Using changes in binding globulins to assess oral contraceptive compliance

Contraception

Volumn 87, Issue 2, 2013, Pages 176-181

  Westhoff, Carolyn L ^a,b   Petrie, Kelsey A ^a,b   Cremers, Serge ^c  

^a NewYork Presbyterian Hospital   (United States)

^b Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Binding globulins; Compliance; Oral contraceptives

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLOBULIN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; THYROXINE BINDING GLOBULIN; TRANSCORTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOLLOW UP; FROZEN SECTION; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; OBESITY; ORAL CONTRACEPTION; OVULATION INHIBITION; PATIENT COMPLIANCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERUM;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; EDUCATIONAL STATUS; ETHINYL ESTRADIOL; ETHNIC GROUPS; FEMALE; HUMANS; LEVONORGESTREL; LIVER; PATIENT COMPLIANCE; SEX HORMONE-BINDING GLOBULIN; THYROXINE-BINDING GLOBULIN; TRANSCORTIN;

EID: 84872148593     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.06.003     Document Type: Article

References (31)

1. P. Boudes Drug compliance in therapeutic trials: a review Control Clin Trials 19 1998 257 268
2. R.B. Haynes, and R. Dantes Patient compliance and the conduct and interpretation of therapeutic trials Control Clin Trials 8 1987 12 19 (Pubitemid 17040574)
3. G.S. Stuart Social desirability bias in family planning studies: a neglected problem Contraception 80 2009 108 112 [Epub 2009 Apr 22]
4. L. Potter, D. Oakley, E. de Leon-Wong, and R. Cañamar Measuring compliance among oral contraceptive users Fam Plann Perspect. 28 1996 154 158
5. C.L. Westhoff, A.H. Torgal, and E.R. Mayeda Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial Obstet Gynecol. 116 2 Pt 1 2010 275 283
6. C.L. Westhoff, A.T. Torgal, E.R. Mayeda, N. Shimoni, F.Z. Stanczyk, and M.C. Pike Predictors of noncompliance in an oral contraceptive clinical trial Contraception 2011 [epub]
7. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, M.C. Pike, and F.Z. Stanczyk Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women Contraception 81 2010 474 480
8. R. Sitruk-Ware, and A. Nath Metabolic effects of contraceptive steroids Rev Endocr Metab Disord. 12 2 2011 63 75
9. N. Van Der Vange, M.A. Blankenstein, H.J. Kloosterboer, A.A. Haspels, and J.H. Thijssen Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone Contraception 41 1990 345 352 (Pubitemid 20134343)
10. H. Kuhl, G. Gahn, G. Romberg, P.H. Althoff, and H.D. Taubert A randomize cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters: II. Effects upon thyroid function, gastrin, STH, and glucose tolerance Contraception 32 1985 97 107 (Pubitemid 15227622)
11. R. Strufaldi, L.M. Pompei, and M.L. Steiner Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels Contraception 2010 82147 82154
12. W. Kuhnz, T. Staks, and G. Jutting Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum Contraception 50 1994 563 579
13. R. Sitruk-Ware, G. Plu-Bureau, and J. Menard Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study J Clin EndOCPrinol Metab 92 2007 2074 2079 [Epub 2007 Mar 20] (Pubitemid 46997103)
14. S. Song, J.K. Chen, and P.J. Yang A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel Contraception 45 1992 523 532
15. I.H. Thorneycroft, F.Z. Stanczyk, K.D. Bradshaw, S.A. Ballagh, M. Nichols, and M.E. Weber Effect of low-dose oral contraceptives on androgenic markers and acne Contraception 60 1999 255 262 (Pubitemid 30100600)
16. I. Wiegratz, E. Kutschera, and J.H. Lee Effect of four different oral contraceptives on various sex hormones and serum-binding globulins Contraception 67 2003 25 32 (Pubitemid 36084284)
17. G.L. Hammond, M.S. Langley, P.A. Robinson, S. Nummi, and L. Lund Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel Fertil Steril 42 1984 44 51 (Pubitemid 14086149)
18. U.M. Ågren, M. Anttila, K. Mäenpää-Liukko, M.L. Rantala, H. Rautiainen, and W.F. Sommer Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function Eur J Contracept Reprod Health Care 16 6 2011 458 467 [Epub 2011 Sep 26]
19. U.J. Gaspard, M.A. Romus, D. Gillain, J. Duvivier, E. Demey-Ponsart, and P. Franchimont Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel Contraception 27 1983 577 590 (Pubitemid 13045209)
20. J. Endrikat, H. Blode, C. Gerlinger, P. Rosenbaum, and W. Kuhnz A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel Eur J Contracept Reprod Health Care 7 2002 79 90 (Pubitemid 34848343)
21. J.W. Goldzieher, T.S. Dozier, and A. de la Pena Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. I. Ethynylestradiol Contraception 21 1980 1 16 (Pubitemid 10129513)
22. J.W. Goldzieher, and S.A. Brody Pharmacokinetics of ethinyl estradiol and mestranol Am J Obstet Gynecol 163 6 Pt 2 1990 2114 2119
23. S. Del Prato Tackling hyperglycemia: a more comprehensive approach Endocr Pract 12 Suppl. 1 2006 63 66 (Pubitemid 44963615)
24. World Health Organization, Department of Reproductive Health Medical eligibility criteria for contraceptive use 3rd edition 2004 World Health Organization Geneva
25. Q. Lu, and R. Elston Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes Am J Hum Genet 82 2008 641 651 (Pubitemid 351726118)
26. T. Tape Interpreting Diagnostic Tests http://gim.unmc.edu/dxtests/ Default.html Accessed March 14 2012
27. B. Musa, U. Seal, and R. Doe Elevation of certain plasma proteins in man following estrogen administration: a dose-response relationship J Clin Endocrinol Metab 25 9 1965 1163 1166
28. T.G. Brien Human corticosteroid binding globulin Clin Endocrinol (Oxf) 14 1981 193 212 (Pubitemid 11053366)
29. W. Junge, U. Mellinger, S. Parke, and M. Serrani Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single centre study Clin Drug Investig 31 2011 573 584
30. S. Zeun, M. Lu, A. Uddin, B. Zeiler, D. Morrison, and H. Blode Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest Eur J Contracept Reprod Health Care 14 2009 221 232
31. A. Teichmann Pharmacology of estradiol valerate/dienogest Climacteric 6 Suppl. 2 2003 17 23